MAXZIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Maxzide, and what generic alternatives are available?
Maxzide is a drug marketed by Aurobindo Pharma Usa and is included in one NDA.
The generic ingredient in MAXZIDE is hydrochlorothiazide; triamterene. There are thirty-two drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; triamterene profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MAXZIDE?
- What are the global sales for MAXZIDE?
- What is Average Wholesale Price for MAXZIDE?
Summary for MAXZIDE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 134 |
Clinical Trials: | 1 |
Drug Prices: | Drug price information for MAXZIDE |
DailyMed Link: | MAXZIDE at DailyMed |
Recent Clinical Trials for MAXZIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
VA Office of Research and Development | |
US Department of Veterans Affairs |
US Patents and Regulatory Information for MAXZIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma Usa | MAXZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-001 | Oct 22, 1984 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Aurobindo Pharma Usa | MAXZIDE-25 | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-003 | May 13, 1988 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MAXZIDE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Aurobindo Pharma Usa | MAXZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-001 | Oct 22, 1984 | ⤷ Sign Up | ⤷ Sign Up |
Aurobindo Pharma Usa | MAXZIDE | hydrochlorothiazide; triamterene | TABLET;ORAL | 019129-001 | Oct 22, 1984 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MAXZIDE
See the table below for patents covering MAXZIDE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Philippines | 21355 | PHARMACEUTICAL COMBINATION COMPOSITION AND ASSOCIATED METHOD | ⤷ Sign Up |
Austria | 51147 | ⤷ Sign Up | |
Hong Kong | 46285 | COSMETIC COMPOSITIONS FOR THE TREATMENT OF DRY SKIN | ⤷ Sign Up |
Japan | H0231053 | ⤷ Sign Up | |
Philippines | 20531 | PHARMACEUTICAL COMBINATION COMPOSITION AND ASSOCIATED METHOD | ⤷ Sign Up |
Malaysia | 8500566 | COSMETIC COMPOSITIONS FOR THE TREATMENT OF DRY SKIN | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MAXZIDE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0480717 | 98C0025 | Belgium | ⤷ Sign Up | PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215 |
0443983 | C00443983/03 | Switzerland | ⤷ Sign Up | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
0454511 | SPC/GB99/008 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
0503785 | CA 2011 00026 | Denmark | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
0502314 | C300095 | Netherlands | ⤷ Sign Up | PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419 |
0502314 | SPC/GB02/037 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |